Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Clin Cancer Res. 2022 Dec 1;28(23):5040–5048. doi: 10.1158/1078-0432.CCR-21-4290

Figure 3. Progression-free survival in patients by p16 and TP53 status.

Figure 3.

(A) Progression-free survival in p16 (−) (n=31) and p16 (+) (n=21) patients receiving everolimus (E) versus placebo (P). (B) Progression-free survival in TP53 wild-type (WT) (n=21) and TP53 mutant (mut) (n=23) patients receiving everolimus (E) versus placebo (P).